Resistance to trametinib (MEKs inhibitor) treatment via FGFR1-dependent activation of ERKs and AKT was also observed in lung and pancreatic cancer cells with mutated KRAS [61]. Here, FGFR1 is linked to familial pancreatic carcinoma.